A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)
Public ClinicalTrials.gov record NCT01467479. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open Label,Phase 3 Study of Telaprevir in Combination With Peginterferon Alfa 2a (Pegasys®) and Ribavirin (Copegus®) in Subjects Coinfected With Genotype 1 Hepatitis C Virus and Human Immunodeficiency Virus Type 1(HCV/HIV-1)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to treat human immunodeficiency virus (HIV) and Hepatitis C Virus (HCV) co-infected subjects with telaprevir, pegylated interferon alfa-2a (Peg-IFN-alfa-2a), and ribavirin (RBV) to achieve undetectable hepatitis C virus ribonucleic acid (HCV RNA) 12 weeks after the last planned dose of study drug.
Study identification
- NCT ID
- NCT01467479
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 185 participants
Conditions and interventions
Conditions
Interventions
- Telaprevir Drug
- Ribavirin Drug
- Pegylated Interferon Alfa-2a Biological
- Highly Active Antiretroviral Therapy (HAART) Drug
Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 2011 (Type not available)
- Primary completion
- Feb 2014 (Actual)
- Completion
- Feb 2014 (Actual)
- Last update posted
- Mar 17, 2015
2011 – 2014
United States locations
- U.S. sites
- 46
- U.S. states
- 26
- U.S. cities
- 45
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alabama | Birmingham | Alabama | — | — |
| California | Bakersfield | California | — | — |
| California | Beverly Hills | California | — | — |
| California | Coronado | California | — | — |
| California | Los Angeles | California | — | — |
| California | Oakland | California | — | — |
| California | Palo Alto | California | — | — |
| California | Sacremento | California | — | — |
| California | San Diego | California | — | — |
| California | San Francisco | California | — | — |
| Connecticut | New Haven | Connecticut | — | — |
| DC | Washington D.C. | District of Columbia | — | — |
| Washington, DC | Washington D.C. | District of Columbia | — | — |
| Florida | Bay Pines | Florida | — | — |
| Florida | Jacksonville | Florida | — | — |
| Florida | Miami | Florida | — | — |
| Florida | Orlando | Florida | — | — |
| Florida | West Palm Beach | Florida | — | — |
| Georgia | Atlanta | Georgia | — | — |
| Georgia | Decatur | Georgia | — | — |
| Illinois | Chicago | Illinois | — | — |
| Maine | Portland | Maine | — | — |
| Maryland | Baltimore | Maryland | — | — |
| Maryland | Lutherville | Maryland | — | — |
| Massachusetts | Springfield | Massachusetts | — | — |
| Michigan | Detroit | Michigan | — | — |
| Minnesota | Minneapolis | Minnesota | — | — |
| Missouri | Kansas City | Missouri | — | — |
| Missouri | St Louis | Missouri | — | — |
| New Jersey | Newark | New Jersey | — | — |
| New Mexico | Santa Fe | New Mexico | — | — |
| New York | New York | New York | — | — |
| New York | Rochester | New York | — | — |
| New York | The Bronx | New York | — | — |
| North Carolina | Durham | North Carolina | — | — |
| Ohio | Cincinnati | Ohio | — | — |
| Ohio | Cleveland | Ohio | — | — |
| Oregon | Portland | Oregon | — | — |
| Pennsylvania | Philadelphia | Pennsylvania | — | — |
| Rhode Island | Providence | Rhode Island | — | — |
| South Carlonia | Columbia | South Carolina | — | — |
| Texas | Dallas | Texas | — | — |
| Texas | Houston | Texas | — | — |
| Utah | Salt Lake City | Utah | — | — |
| Virginia | Richmond | Virginia | — | — |
| Washington | Seattle | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01467479, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 17, 2015 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01467479 live on ClinicalTrials.gov.